Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vistagen

< Previous 1 2 3 Next >
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Stockholder-Approved Reverse Stock Split
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Receives New European Patent for AV-101
From Vistagen
Via Business Wire
Tickers VTGN
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Cowen 43rd Annual Health Care Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Acquire Pherin Pharmaceuticals
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Stifel 2022 Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
From Vistagen
Via Business Wire
Tickers VTGN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.